As a part of this deal, APL also acquired high profile OTC ... with China National Pharmaceutical Group Corporation (Sinopharm) to divest in its subsidiary company Aurobindo (Datong) Bio Pharma ...

Aurobindo Pharma reported a consolidated revenue increase of 10.6% year-on-year, reaching Rs 8,382 crore in Q4 FY25.

Shareholder Return: 3-year average, Sales Growth: 3-year Compounded Annual Growth Rate, Return On Equity: 3-year Return on Equity. The company, which focuses on the formulations business, has ...

Nowhere is India’s epithet—pharmacy of the world—more apt than in the case of some big pharmaceutical companies. One such company is Aurobindo Pharma, which has steadily grown over the past ...

On a fiscal year basis (FY25), Aurobindo Pharma’s PAT increased 10% y-o-y to ₹3,484 crore from ₹3,169 crore in FY24, showing better full year profitability. Annual income at the company ...

Aurobindo Pharma said in a regulatory filing. For the full year ended March 31, 2025, the company said its PAT rose 10 per cent to Rs 3,484 crore against Rs 3,169 crore in FY24. The total revenue ...

Aurobindo Pharma, a leading pharmaceutical company, has announced its financial results for the second quarter of FY24, ending on November 9, 2023. The company reported a significant increase in ...

WASHINGTON (KDKA) - Two lots of blood medication are being recalled. Aurobindo Pharma USA is recalling some Quinapril and Hydrochlorothiazide tablets because they contain too high levels of ...

A pharmaceutical company is recalling a blood pressure medication due to a potential cancer risk, the FDA announced this week. Aurobindo Pharma USA is recalling two lots of quinapril and ...